The case for & against
Bull & Bear analysis
Genmab A/S (NASDAQ:GMAB) is a prominent biotechnology company specializing in the development of innovative antibody therapies for oncology, particularly targeted therapies that meet significant unmet medical needs. With a solid footing in the oncology market, Genmab has positioned itself as a leader through its proprietary platform and strategic partnerships, focusing on bringing unique therapies, like their bispecific antibodies for hematological malignancies, to market. The recent approval of TEPKINLY® for follicular lymphoma solidifies their reputation for innovation in this critical medical field.
Bull says
- ↑Q1 2026 revenue +25% YoY to $176M; Epkinley sales +52% to $137M
- ↑European approval of TEPKINLY showed 79% reduction in disease progression
- ↑Operating profit rose 45% YoY amid disciplined capital allocation
- ↑Commercial expansion in Europe and Japan broadens market reach
- ↑Strong profitability factors and manageable leverage support financial health
- ↑Unique bispecific antibody platform underpins robust competitive moat
Bear says
- ↓Negative earnings yield signals potential valuation overhang at current prices
- ↓Market adoption risk: TEPKINLY uptake may lag in academic settings
- ↓Regulatory uncertainty for RINA-S and Apcaritumab adds approval risk
- ↓Pipeline readout misses could sharply erode investor sentiment
- ↓High debt post-$5.5B offering and $2.7–2.9B expenses increase leverage risk
- ↓Analyst downgrades and elevated short interest reflect market skepticism
Investment themes with GMAB
Health services for families and elective treatments
Value-oriented stocks outside domestic markets
Earnings Call · Q1 2026 · Mgmt. Guidance
Transcript signals
Bull points
- The feedback from physicians, hospitals, and health systems has been extremely positive with not only the unprecedented data as Talia referenced, but also the convenience and being able to realize the value closer to the patient's home.
- we'll probably at some point going to update that curve and present it in the data, but I think the more meaning we got is going to be the actual study. So... You know, we said one or two of them will be out this year. And so that is probably the more meaningful data set and relevant to the brand and to the company.
- the phase three is actively enrolling We haven't guided the VISTA community about readouts, but what I can say is the activation and enrollment is going very well.
Bear points
- I think that it's very apparent what we already presented with 17 months follow-up, which is not negligible. And at this time point, around 30% were censored and alive. And this gives you a kind of magnitude of duration.
- now we are fixated on the phase 3s. which are much more relevant.
- we have tax expense of around $21 million, which equates to an effective tax rate of 28.9%. And here, I do want to pause for a moment and note that we are currently evaluating the integration of merits operations from a tax perspective, so our effective tax rate may experience some volatility as integration activities progress. However, we do anticipate that this is going to normalize within the next 12 to 18 months.